WallStSmart

HealthEquity Inc (HQY)vsOmnicell Inc (OMCL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

HealthEquity Inc generates 11% more annual revenue ($1.31B vs $1.18B). HQY leads profitability with a 16.4% profit margin vs 0.2%. HQY appears more attractively valued with a PEG of 0.89. HQY earns a higher WallStSmart Score of 68/100 (B-).

HQY

Strong Buy

68

out of 100

Grade: B-

Growth: 8.0Profit: 7.0Value: 10.0Quality: 6.5
Piotroski: 4/9

OMCL

Hold

39

out of 100

Grade: F

Growth: 2.7Profit: 4.0Value: 2.0Quality: 6.3
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HQYUndervalued (+33.2%)

Margin of Safety

+33.2%

Fair Value

$115.13

Current Price

$82.47

$32.66 discount

UndervaluedFair: $115.13Overvalued
OMCLSignificantly Overvalued (-13907.4%)

Margin of Safety

-13907.4%

Fair Value

$0.27

Current Price

$34.94

$34.67 premium

UndervaluedFair: $0.27Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HQY3 strengths · Avg: 8.7/10
EPS GrowthGrowth
92.4%10/10

Earnings expanding 92.4% YoY

PEG RatioValuation
0.898/10

Growing faster than its price suggests

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

OMCL2 strengths · Avg: 9.5/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

Areas to Watch

HQY1 concerns · Avg: 4.0/10
P/E RatioValuation
33.4x4/10

Premium valuation, high expectations priced in

OMCL4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
2.3%4/10

2.3% revenue growth

Market CapQuality
$1.57B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.2%3/10

ROE of 0.2% — below average capital efficiency

Profit MarginProfitability
0.2%3/10

0.2% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : HQY

The strongest argument for HQY centers on EPS Growth, PEG Ratio, Operating Margin. Profitability is solid with margins at 16.4% and operating margin at 21.6%. PEG of 0.89 suggests the stock is reasonably priced for its growth.

Bull Case : OMCL

The strongest argument for OMCL centers on Price/Book, Debt/Equity.

Bear Case : HQY

The primary concerns for HQY are P/E Ratio.

Bear Case : OMCL

The primary concerns for OMCL are Revenue Growth, Market Cap, Return on Equity. A P/E of 861.5x leaves little room for execution misses. Thin 0.2% margins leave little buffer for downturns.

Key Dynamics to Monitor

HQY profiles as a mature stock while OMCL is a value play — different risk/reward profiles.

OMCL carries more volatility with a beta of 0.79 — expect wider price swings.

HQY is growing revenue faster at 7.3% — sustainability is the question.

HQY generates stronger free cash flow (102M), providing more financial flexibility.

Bottom Line

HQY scores higher overall (68/100 vs 39/100), backed by strong 16.4% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

HealthEquity Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

HealthEquity, Inc. provides technology-enabled service platforms to consumers and employers in the United States. The company is headquartered in Draper, Utah.

Omnicell Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Omnicell, Inc., provides medication management automation solutions and adherence tools for health care systems and pharmacies in the United States and internationally. The company is headquartered in Mountain View, California.

Want to dig deeper into these stocks?